Stuart Orkin
Stuart H. Orkin | |
---|---|
Nationality | American |
Fields | Pediatric oncology |
Institutions | Dana–Farber/Harvard Cancer Center |
Education | Massachusetts Institute of Technology, Harvard Medical School |
Stuart H. Orkin is an American physician, stem cell biologist and researcher in pediatric hematology-oncology. He is the David G. Nathan Professor of Pediatrics at Harvard Medical School and is the chairman of pediatric oncology at the Dana–Farber/Harvard Cancer Center. Orkin's research has focused on the genetic basis of blood disorders. He is a member of the National Academy of Sciences and the Institute of Medicine.
Early life
Orkin grew up in Manhattan, where his father was a urologist. He studied biology as an undergraduate at the Massachusetts Institute of Technology and earned a medical degree from Harvard Medical School. He did postdoctoral research in molecular biology at the National Institutes of Health under geneticist Philip Leder. While Orkin was completing his training in hematology-oncology, his department chair, David G. Nathan, allowed him to establish his own research laboratory.[1]
Career
Orkin is the David G. Nathan Professor of Pediatrics at Harvard Medical School and chairs the Department of Pediatric Oncology at the Dana–Farber/Harvard Cancer Center.[2] He has been on the Harvard Medical School faculty since the late 1970s and has been a Howard Hughes Medical Institute investigator since 1986.[3][4]
In the 1970s and 1980s, Orkin conducted research that identified genetic mutations associated with a group of blood disorders known as the thalassemias.[5] Later, he and his team cloned a gene causing chronic granulomatous disease, marking the first time that a disease-causing gene was cloned without the researchers already knowing the protein coded by the gene.[5] Today, his research lab examines transcriptional regulators of cell specification and differentiation.[6] In September 2015, Orkin published a study in the journal Nature showing a small section of DNA which could be responsive to gene therapy for sickle-cell disease.[7]
Honors and awards
In 1987, Orkin received the E. Mead Johnson Award.[8] Elected to the National Academy of Sciences in 1991, Orkin won the Jessie Stevenson Kovalenko Medal from that organization in 2013.[9] He was elected to the Institute of Medicine in 1992.[10] In 1993, he received the Warren Alpert Foundation Prize.[11] The American Society of Hematology named Orkin one of its Legends in Hematology in 2008.[12] The American Society of Human Genetics honored Orkin with the 2014 William Allan Award, which recognizes sustained and significant contributions to human genetics.[5]
Personal
Orkin has been married for more than 40 years and has one daughter.[1]
References
- 1 2 Kazazian, Haig (March 2015). "2014 William Allan Award Introduction: Stuart Orkin". American Journal of Human Genetics 96 (3): 352–353. doi:10.1016/j.ajhg.2014.11.018. Retrieved November 11, 2015.
- ↑ "Stuart H. Orkin, MD". Dana–Farber/Harvard Cancer Center. Retrieved November 11, 2015.
- ↑ "Stuart Orkin, MD". Harvard Stem Cell Institute. Retrieved November 11, 2015.
- ↑ "Stuart H. Orkin, MD". Howard Hughes Medical Institute. Retrieved November 11, 2015.
- 1 2 3 "ASHG honors Stuart H. Orkin with William Allan Award". American Society of Human Genetics. June 26, 2014. Retrieved November 11, 2015.
- ↑ "BBS Faculty Member – Stuart Orkin". Harvard Medical School. Retrieved November 11, 2015.
- ↑ Goldberg, Carey (September 21, 2015). "In step toward genetic fix, scientists pinpoint ‘Achilles heel’ of sickle cell disease". WBUR-FM. Retrieved November 11, 2015.
- ↑ "E. Mead Johnson Award in Pediatric Research". American Pediatric Society. Retrieved November 11, 2015.
- ↑ "Stuart H. Orkin". National Academy of Sciences. Retrieved November 11, 2015.
- ↑ "IOM Member- Stuart H. Orkin, M.D.". Institute of Medicine. Retrieved November 11, 2015.
- ↑ "1993 Recipient: Stuart H. Orkin". Warren Alpert Foundation. Retrieved November 11, 2015.
- ↑ "Legends in Hematology". American Society of Hematology. Retrieved November 11, 2015.